Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25803
Title: Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease.
Austin Authors: Liu, Yu-Hui;Wang, Jun;Li, Qiao-Xin;Fowler, Christopher J;Zeng, Fan;Deng, Juan;Xu, Zhi-Qiang;Zhou, Hua-Dong;Doecke, James D;Villemagne, Victor L ;Lim, Yen Ying;Masters, Colin L ;Wang, Yan-Jiang
Affiliation: Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
The Australian E-Health Research Centre, CSIRO, Herston, Queensland, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Molecular Imaging and Therapy
Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China
Issue Date: 1-Jan-2021
metadata.dc.date: 2021-01-01
Publication information: Science Advances 2021; 7(1): eabb0457
Abstract: The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer's disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25803
DOI: 10.1126/sciadv.abb0457
ORCID: 0000-0001-7320-8353
0000-0001-6693-172X
0000-0003-1397-0359
0000-0003-4559-292X
0000-0002-5536-3293
0000-0002-5832-9875
0000-0003-3072-7940
0000-0002-6227-6112
PubMed URL: 33523832
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on May 17, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.